Dihydromyricetin alleviates TNF-α-induced endothelial dysfunction via miR-21 expression downregulation, resulting in enhanced eNOS phosphorylation and NO production in vitro [177]. The gene discussed is NOS3; the disease is endothelial dysfunction.